A low dose of a drug called naltrexone is a good option for patients with orofacial and chronic pain without the risk of addiction, according to the University of Michigan School of Dentistry.
Naltrexone is a semisynthetic opioid first developed in 1963 as an oral alternative to naloxone, the nasal spray used to reverse drug overdoses. When prescribed at doses of 50 to 100 mg, naltrexone blocks the effects of alcohol and opioids.
Low-dose naltrexone has been used off-label for years to treat chronic pain, but researchers at the school said they have conducted the first in-depth, systematic review of the literature to determine if it is a good option for patients and deserving of more study.
“We found a reduction in pain intensity and improvement in quality of life, and a reduction in opioid use for patients with chronic pain,” said first author Elizabeth Hatfield, clinical lecturer in the Department of Oral and Maxillofacial Surgery and Hospital Dentistry.
Hatfield hopes to initiate a randomized control trial of low-dose naltrexone. Low doses between 0.1 and 4.5 mg work by acting on a unique cellular pathway in the nervous system, through which it delivers chronic pain relief without opioids, Hatfield said.
If patients are working with a physician to treat pain, Hatfield continued, it’s appropriate for them to raise the topic of low-dose naltrexone as a possible alternative.
Chronic pain is pain that persists for several months, or after the initial injury trauma has healed. According to some estimates, the school said, chronic pain affects up to 40% of Americans.
Treating chronic pain is frustrating for both clinicians and patients, the school said, and that frustration is compounded by a hesitation to prescribe opioids for pain.
Now, the way clinicians and scientists think about chronic pain is changing, the school said. It’s now thought that some chronic pain has more to do with how our body reports pain to the brain than the actual injury.
“Normally, chronic pain leads your body to go through a sensitization process whereas your nervous system becomes more sensitive, and this can happen even to nonpainful stimuli,” said Hatfield.
“The way I like to explain it to learners or patients is how a sunburn makes you feel, when things that are normally feel okay hurt, like a warm shower or a sheet touching your skin,” she said.
This concept of the nervous system being sensitized is promoted by cells called glial cells. Low-dose naltrexone targets these cells that keep the nervous system sensitized, thereby reducing the pain threshold and the sensitivity of the nervous system over time.
Traditional pain management has focused on treating the injury or trauma site, but low-dose naltrexone works on the overactive nervous system.
“Low-dose naltrexone begins to address the cause of pain and not just mask it, which allows us to better target diseases causing chronic pain, as well as potentially consider pain control outside of opioid use,” Hatfield said.
It is best used on centralized pain disorders, conditions where the nervous system is in that hyperexcited state, Hatfield said. These conditions include myalgia, complex regional pain syndrome, and temporomandibular joint disorders, among others.
Low-dose naltrexone also is inexpensive and has few side effects. However, it is not an option for people who use alcohol or opioids regularly.
Hatfield became interested in the field of orofacial pain after study coauthor Lawrence Ashman, clinical assistant professor of dentistry, started a residency in orofacial pain in 2018. Two years later, Hatfield was the first graduate of the two-year Orofacial Pain Residency program in the OMS/Hospital Dentistry Department.
There are only 13 residencies in orofacial pain in the country, Hatfield said. However, the pain specialty makes sense for dentistry because this pain is related to joints and muscles surrounding the oral cavity and hasn’t been previously “owned” by dentists or medicine.
Many patients are first exposed to opioids through dentistry. While there is a place for well-managed opioid treatment for chronic pain patients, alternative treatments are needed, Hatfield said.
The study, “Use of Low-Dose Naltrexone in the Management of Chronic Pain Conditions: A Systematic Review,” was published by The Journal of the American Dental Association.
Related Articles
Patients With Dental Anxiety Take More Painkillers After Tooth Extractions
Gene Therapy Tapped to Treat Oral Cancer Pain
Sleep Bruxism Could Play a Role in TMD Diagnoses
